Anne‐Marie Maddox

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 578 citations

Medicine, Oncology, Pharmacology +17

Immunomodulation with interferon‐gamma and colony‐stimulating factors for refractory fungal infections in patients with leukemia

María Cecilia Dignani, John Rex, Ka‐Wah Chan et al. · Cancer · 2005 · 68 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Superior vena cava obstruction in small cell bronchogenic carcinoma clinical parameters and survival

Anne‐Marie Maddox, Manuel Valdivieso, John M. Lukeman et al. · Cancer · 1983 · 53 citations · Full text

Medicine, Oncology, Surgery +12

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Soham D. Puvvada, Hongli Li, Lisa M. Rimsza et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 41 citations · Full text

Life Sciences, Immunology, Oncology +17

Functional Outcomes of Chemoradiation in Patients with Head and Neck Cancer

Ozlem E. Tulunay‐Ugur, Christopher McClinton, Zachary T. Young et al. · Otolaryngology · 2012 · 37 citations · Full text

Medicine, Oncology, Radiation Oncology +14